StemCells Inc (STEM) : Paradigm Financial Advisors has sold out all of its stake in StemCells Inc during the most recent quarter, according to the disclosure filed by the company on Jul 26, 2016 with the SEC. The investment management company has sold out 1,000 shares of StemCells Inc which is valued at $406.
Other Hedge Funds, Including , Msi Financial Services Inc boosted its stake in STEM in the latest quarter, The investment management firm added 1 additional shares and now holds a total of 5 shares of StemCells Inc which is valued at $2. Barry Investment Advisors sold out all of its stake in STEM during the most recent quarter. The investment firm sold 860 shares of STEM which is valued $327.Creative Planning reduced its stake in STEM by selling 5,415 shares or 85.44% in the most recent quarter. The Hedge Fund company now holds 923 shares of STEM which is valued at $354.
StemCells Inc closed down -0.0068 points or -1.79% at $0.3735 with 2,64,696 shares getting traded on Friday. Post opening the session at $0.4, the shares hit an intraday low of $0.37 and an intraday high of $0.4098 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Many Wall Street Analysts have commented on StemCells Inc. StemCells Inc was Downgraded by Maxim Group to ” Hold” on May 31, 2016.
StemCells Inc. is engaged in the research development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company’s lead product development program is its CNS Program in which it is developing applications for HuCNS-SC cells its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system. The CNS consists of the brain spinal cord and eye and it is stem cell company in clinical development for indications in all three compartments comprising the CNS which include with respect to the brain with respect to the spinal cord and with respect to the eye. The Phase I clinical trial was completed in Pelizeaus-Merzbacher Disease Neuronal Ceroid Lipofuscinosis and Phase I/II clinical trial in multiple sites for chronic spinal cord injury was completed.